Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treosulfan may become standard in allo-HCT for AML/MDS

Key clinical point: A treosulfan-based conditioning regimen could become a standard prior to allogeneic transplant in elderly or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Major finding: Event-free survival at 2 years was 65.7% and 51.2%, respectively, for the treosulfan- and busulfan-based conditioning regimens (P = .0000001).

Study details: Final analysis of the randomized phase 3 MC-FludT.14/L study, including 551 patients with AML or MDS.

Disclosures: Dr. Beelen reported honoraria, travel support, and trial documentation support provided by medac GmbH, which sponsored the trial.

Citation:

Beelen DW et al. TCT 2019, Abstract 4.